Comparison Log
2025-12-15 02:43:41.527411
mwtab Python Library Version: 2.0.0
Source:      https://www.metabolomicsworkbench.org/rest/study/analysis_id/AN006057/mwtab/...
Study ID:    ST003691
Analysis ID: AN006057
Status:      Inconsistent

mwTab files contain different blocks: "{'FACTORS'}"
Sections "COLLECTION" contain missmatched items: {'COLLECTION_SUMMARY': ["p.Arg141His/Phe119LeuPMM2 fibroblasts were a gift from Prof. Flemming Skovby (rigshospitalet.dk -informed consent obtained from patients in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki). Cells were immortalised as described in Monticelli et al. 2022 [1] and grown in RPMI medium supplemented with 10% Fetal Bovine Serum, 2\u202fmM glutamine, 0.5\u202fmg/mL penicillin, 0.5\u202fmg/mL streptomycin, and non-essential amino acids at 37\u202f°C in 5% humidified CO2. -/-PMM1 was generated by the insertion of a puromycin resistance cassette into the first exon of PMM1, using the Origene kit KN202004. Following the manufacturer's instructions, puromycin -up to 0.3 ng/mL- was used for the selection, and resistant cells were analysed via PCR to verify the correct insertion. Positive cells were grown and further analysed via RT-qPCR and immunoblot to confirm the knock-out. For metabolomics analysis, cells from confluent 150 cm2 plates were washed with PBS and enzymatically detached using trypsin, then pelleted in PBS and washed again for 3 times. [1] Monticelli, L. Liguori, M. Allocca, A. Bosso, G. Andreotti, J. Lukas, M.C. Monti, E. Morretta, M.V. Cubellis, B. Hay Mele, Drug Repositioning for Fabry Disease: Acetylsalicylic Acid Potentiates the Stabilization of Lysosomal Alpha-Galactosidase by Pharmacological Chaperones, International Journal of Molecular Sciences 23 (2022) 5105. https://doi.org/10.3390/ijms23095105", "p.Arg141His/Phe119LeuPMM2 fibroblasts were a gift from Prof. Flemming Skovby (rigshospitalet.dk -informed consent obtained from patients in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki). Cells were immortalised as described in Monticelli et al. 2022 [1] and grown in RPMI medium supplemented with 10% Fetal Bovine Serum, 2\u202fmM glutamine, 0.5\u202fmg/mL penicillin, 0.5\u202fmg/mL streptomycin, and non-essential amino acids at 37\u202f°C in 5% humidified CO2. -/-PMM1 was generated by the insertion of a puromycin resistance cassette into the first exon of PMM1, using the Origene kit KN202004. Following the manufacturer''s instructions, puromycin -up to 0.3 ng/mL- was used for the selection, and resistant cells were analysed via PCR to verify the correct insertion. Positive cells were grown and further analysed via RT-qPCR and immunoblot to confirm the knock-out. For metabolomics analysis, cells from confluent 150 cm2 plates were washed with PBS and enzymatically detached using trypsin, then pelleted in PBS and washed again for 3 times. [1] Monticelli, L. Liguori, M. Allocca, A. Bosso, G. Andreotti, J. Lukas, M.C. Monti, E. Morretta, M.V. Cubellis, B. Hay Mele, Drug Repositioning for Fabry Disease: Acetylsalicylic Acid Potentiates the Stabilization of Lysosomal Alpha-Galactosidase by Pharmacological Chaperones, International Journal of Molecular Sciences 23 (2022) 5105. https://doi.org/10.3390/ijms23095105"]}